Goldman Sachs Maintains Neutral on LifeStance Health Gr, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Jamie Perse has maintained a Neutral rating on LifeStance Health Group (LFST) but has reduced the price target from $9 to $8.

November 22, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs analyst Jamie Perse maintains a Neutral rating on LifeStance Health Group but lowers the price target from $9 to $8.
The reduction in price target by a major analyst like Goldman Sachs can lead to a negative perception among investors, potentially causing a short-term dip in the stock price. However, since the rating remains Neutral, the impact might be moderate rather than severe.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100